BioWorld

Aug. 8, 2008

Ahead of OncoGenex Merger, Sonus Adds Caspase Program

Compliance in Off-Label and Journal Articles

Other News To Note

Clinic Roundup

Appointments And Advancements

Celgene Calls it Quits in GPC Satraplatin Deal

Celgene Corp. has ended its nearly three-year partnership with embattled German firm GPC Biotech AG on its prostate cancer drug satraplatin. (BioWorld Today) Read More

Acorda's $114M Offering to Support NDA, Launch

Today's news in brief

BioWorld

BioWorld briefs for July 17, 2026.

Celia trial: data strong, analysts skeptical

BioWorld

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026

Elderly hands holding broken brain structure

Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability

BioWorld Science

Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....